Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: LY3316531 - IV
Drug: Placebo - IV
Drug: LY3316531 - SC

First Posted Date: 2018-02-01

Last Posted Date: 2023-09-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 63

Registration Number: NCT03418493

Locations: 🇺🇸
PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore, Maryland, United States
🇺🇸
Parexel Early Phase Unit at Glendale, Glendale, California, United States

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Prexasertib

First Posted Date: 2018-01-29

Last Posted Date: 2022-08-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 172

Registration Number: NCT03414047

Locations: 🇺🇸
Kaiser Permanente Medical Center, Vallejo, California, United States
🇬🇧
Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
🇺🇸
University of Southern Florida School of Medicine, Gainesville, Florida, United States

and more 43 locations

A Study of Lasmiditan in Healthy Elderly Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Lasmiditan

First Posted Date: 2018-01-23

Last Posted Date: 2019-12-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT03406260

Locations: 🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States

A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: LY900014
Drug: Insulin Lispro

First Posted Date: 2018-01-23

Last Posted Date: 2020-05-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 31

Registration Number: NCT03407118

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Fukuoka, Japan

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Pegilodecakin
Drug: Nivolumab

First Posted Date: 2017-12-26

Last Posted Date: 2020-09-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 52

Registration Number: NCT03382912

Locations: 🇺🇸
Glendale Adventist Medical Center, Los Angeles, California, United States
🇺🇸
Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States
🇺🇸
Millennium Oncology, Houston, Texas, United States

and more 32 locations

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Pegilodecakin
Drug: Pembrolizumab

First Posted Date: 2017-12-26

Last Posted Date: 2021-01-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 101

Registration Number: NCT03382899

Locations: 🇺🇸
Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇺🇸
The Oncology Institute of Hope and Innovation, Whittier, California, United States
🇺🇸
Orchard Healthcare Research Inc, Skokie, Illinois, United States

and more 71 locations

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Biological: Pegilodecakin

First Posted Date: 2017-12-22

Last Posted Date: 2019-04-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 12

Registration Number: NCT03381547

Locations: 🇺🇸
PPD Development, Austin, Texas, United States

A Study of Tirzepatide (LY3298176) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2017-12-18

Last Posted Date: 2024-02-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 52

Registration Number: NCT03375463

Locations: 🇺🇸
Covance, Dallas, Texas, United States

Assessment of Mealtime Bolus Insulin Behavior

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Device: Continuous Glucose Monitoring
Drug: Insulin Lispro

First Posted Date: 2017-12-11

Last Posted Date: 2019-08-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 79

Registration Number: NCT03368807

Locations: 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸
AMCR Institute, Inc., Escondido, California, United States
🇺🇸
Science 37 Inc, Los Angeles, California, United States

and more 3 locations

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Placebo
Drug: Donanemab
Drug: LY3202626

First Posted Date: 2017-12-08

Last Posted Date: 2022-10-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 272

Registration Number: NCT03367403

Locations: 🇨🇦
Toronto Memory Program, Toronto, Ontario, Canada
🇺🇸
Texas Neurology, PA, Dallas, Texas, United States
🇺🇸
Bradenton Research Center, Bradenton, Florida, United States

and more 57 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy